SRA 141

Drug Profile

SRA 141

Alternative Names: AS-141; PNT-141; SRA141

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Carna Biosciences; CrystalGenomics; SBI Biotech
  • Developer Sierra Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cdc7-ASK kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Jan 2017 ProNAi Therapeutics is now called Sierra Oncology
  • 26 May 2016 PNT 141 licensed to ProNai Therapeutics worldwide
  • 26 May 2016 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top